Arctic Bioscience Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Christer Valderhaug

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	0.06%
Permanencia media de la dirección	6.2yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Christer Valderhaug (52 yo)

no data

Permanencia

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Harald Nordal	Co-Founder & Chairman	9.1yrs	sin datos	0.079% € 3.5k
Christer Valderhaug	Chief Executive Officer	no data	sin datos	0.055% € 2.4k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.6yrs	sin datos	1.83% € 80.6k
Jone Slinning	Chief Financial Officer	2.6yrs	sin datos	0.052% € 2.3k
Per Sæbo	Chief Operating Officer	12.3yrs	sin datos	0.090% € 4.0k
Daniele Mancinelli	Chief Technical Officer	12.3yrs	sin datos	0.0079% € 346.6
Steffen Eidal	Senior Vice President of Sales & Marketing	2.6yrs	sin datos	sin datos
Yuming Feng	Executive Vice President of Global Business Development	6.2yrs	sin datos	sin datos
Runhild Gammelsæter	Global Medical Director	5.3yrs	sin datos	0.14% € 6.0k

6.2yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 9TD es experimentado (6.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Harald Nordal	Co-Founder & Chairman	9.1yrs	sin datos	0.079% € 3.5k
Jostein Dalland	Independent Board Member	4.7yrs	sin datos	sin datos
Tore Andreas Tonseth	Board Member	3.8yrs	sin datos	sin datos
Asbjorn Solevagseide	Board Member	5.6yrs	sin datos	sin datos
Jan Vartdal	Board Member	9.1yrs	sin datos	4.1% € 180.4k
Per Eggesbo	Board Member	8.8yrs	sin datos	sin datos
Hu Cao	Board Member	3.8yrs	sin datos	sin datos
Marita Holstad	Director	3.8yrs	sin datos	sin datos

5.1yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 9TD se considera experimentada (5.1 años de antigüedad promedio).

Arctic Bioscience Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Recent updates

Arctic Bioscience AS Provides Revenue Guidance for the Year 2024

New major risk - Market cap size

Arctic Bioscience Announces Top-Line Results from Phase 2b HeROPA Study

New major risk - Financial position

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings released: kr1.79 loss per share (vs kr1.39 loss in FY 2022)

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings released

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad